Scalable, decentralised, medical radioisotope supply
Our platform enables for neutron-produced radioisotopes, what cyclotrons enable for proton-produced radioisotopes.
﹇
↓
﹈
Global supply chains rely on ageing fission reactors, many of which will go offline in the 2030s. Astral’s compact technology enables domestic, decentralised production direct to those in need.
The Advantage
Reduced Decay
By producing isotopes where they are needed, our technology helps reduce the need to transport isotopes across borders.
Negligible waste
Fusion produces significantly less nuclear waste than fission.
Setup time
We are now capable of producing dozens of MSF reactors per year which can be deployed in weeks once completed.
Isotope Agnostic
Copper-64, Copper-67, Actinium-225, Lead-212, Terbium-161, and many others.
Pipeline
Element
2026
2027
2028
2029
Cu-64 | Cu-67
Ac-225 | Pb-212
Novel Isotopes
I-131
Deployable within two years [Project Pending]
